Dr Reddy's rallies 2% on anti cancer drug

Posted By:
Subscribe to GoodReturns

Dr Reddy's rallies 2% on anti cancer drug
Shares in Dr Reddy's Laboratories rallied 2% in trade after an almost 4% gains in trade on Monday.

The sharp rally was on the back of the company getting the approval of the US Food and Drug Administration (USFDA) to launch injectible medicine azacitidine, which is used in the treatment of bone marrow cancer and blood cell disorders.

The shares of the company were last trading at Rs 2352 on the Bombay Stock Exchange. A host of Indian pharma companies have been facing problems with drug exports to the US as the US FDA has issued import warning letters to quite a few of these companies.


Read more about: bse, dr reddys labs
Story first published: Wednesday, September 18, 2013, 12:18 [IST]
Please Wait while comments are loading...
Company Search
Enter the first few characters of the company's name or the NSE symbol or BSE code and click 'Go'